AMSilk Invited to Participate in VISION 2045 Summit

Leaders from across the world will convene at VISION 2045 Summit which takes place alongside COP27 (the U.N. Climate Change Conference) in November AMSilk will be attending and participating in a panel discussion at the Vision 2045 Summit on ‘Commerce and Industry: What’s Next?’ Munich, Germany, 2 November 2022 – AMSilk GmbH (“AMSilk”), a world leader […]

Enzyre closes Series A financing round of EUR 12M to advance pioneering diagnostic technology platform for hemophilia patients

Funds will be used to accelerate development of proprietary ambulant diagnostic platform and establish manufacturing capabilities Plans to expand platform beyond hemophilia A 02 November 2022, Nijmegen, Netherlands: Enzyre, which is developing breakthrough ambulant diagnostic technology for blood coagulation testing, today announced that it has successfully raised EUR 12 million in a Series A financing […]

ImaginAb Announces First Patient Dosed in Australia in Phase IIb iPREDICT Trial

Los Angeles, California, USA, October 25th, 2022 – ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and next generation radiopharmaceutical therapies (RPT) products, is pleased to announce that the first patient has been dosed at the Macquarie University Hospital in Sydney, Australia as part of its Phase IIb iPREDICT […]

Sequana Medical announces positive top-line results from the North American pivotal alfapump® study (POSEIDON)

 alfapump achieves pre-specified primary effectiveness endpoints with statistical significance at six months post-implantation: 100% median per-patient reduction in therapeutic paracentesis (TP) post- vs pre-implantation (p<0.001) 77% of patients with at least 50% reduction in number of TP post- vs pre-implantation (p<0.001) alfapump primary safety endpoint data in line with expectations On track to file Pre-Market […]

Gadeta Appoints Scientific Advisory Board and Provides Business Update

Utrecht, Netherlands and Boston, Mass., 20 October 2022: Gadeta B.V. (‘Gadeta’), an innovative clinical-stage biopharmaceutical company pioneering the development of gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for solid tumors, today announced the formation of a Scientific Advisory Board comprised of internationally renowned leaders in oncology, T cell biology and strategic drug development. The Scientific […]